Bioprocessing and biomanufacturing focus
Latest
ArticleTesto at CPHI 2026 in Milan: digital monitoring for the pharmaceutical industry
At CPHI 2026, Testo will showcase digital solutions for monitoring, compliance, and supply chain transparency in the pharmaceutical industry.
ArticleNitrosamines: from detection to understanding
Manufacturers are facing a new generation of nitrosamine challenges as NDSRIs demand more sophisticated analytical and risk management strategies.
WebinarBuilding quality and consistency into accelerated cell and gene therapy development
How can cell and gene therapy manufacturers move programmes forward faster without compromising quality, scalability or regulatory readiness?
Featured
Opinion
What will shape the future of advanced therapies in Europe?
Following his opening keynote at this year’s Advanced Therapies Europe conference in Barcelona, Professor Jacob George, MHRA Chief Medical & Scientific Officer, explores the evolving regulatory landscape for advanced therapy medicinal products.
Article
Strategies for scaling complex next-generation biologics
As biologic drug formats grow more sophisticated, scalable success depends on embedding manufacturability, analytics and quality thinking into molecular design from the very beginning of development.
Webinars
- Previous
- Next
Whitepapers
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs in drug discovery
- Receive updates and recommendations tailored to your research interests
More bioprocessing and biomanufacturing
- Article
Testo at CPHI 2026 in Milan: digital monitoring for the pharmaceutical industry
At CPHI 2026, Testo will showcase digital solutions for monitoring, compliance, and supply chain transparency in the pharmaceutical industry.
OpinionHow can we ensure consistency in decentralised cell therapy manufacturing?
Following her presentation at Advanced Therapies Europe, Charlotte Serra navigates the complexities of decentralised cell therapy manufacturing.
ArticlePrecision control for target protein degraders
Target protein degraders offer therapeutic potential, yet their high potency, poor solubility and ultra-low administered doses place significant demands on formulation science, analytical capability, containment and scalable manufacture. Successful development requires solubility enhancement, particle engineering, excipient design, high-potency containment and process development to be considered together from the earliest programme stages.
ArticleNitrosamines: from detection to understanding
Manufacturers are facing a new generation of nitrosamine challenges as NDSRIs demand more sophisticated analytical and risk management strategies.
ArticleTo grow, pharma manufacturers need operations that scale - not just acquisitions
As patent cliffs threaten hundreds of billions in drug revenues and M&A activity reshapes the industry, the companies best placed to capitalise on pharma’s great reshuffling will be those that have standardised their manufacturing operations, unified their asset management and integrated quality systems capable of satisfying an increasingly demanding multi-regulator environment.
ArticleRedefining the standard for recessed lighting in the pharmaceutical industry
Pharmaceutical and chemical manufacturing facilities present some of the most demanding lighting challenges in industry, combining explosive atmospheres, stringent hygiene requirements and complex regulatory requirements. Raytec examines how explosion-protected LED solutions are redefining safety, performance and compliance across hazardous area applications.
ArticleClosing the data integrity gap in pharmaceutical quality control
Pharmaceutical quality control laboratories face growing pressure to strengthen data integrity as regulators scrutinise incomplete records, manual data entry, and disconnected systems.
ArticleTransforming mycoplasma testing for faster biotherapeutic quality control
As biotherapeutic manufacturing accelerates, rapid PCR-based methods are enabling manufacturers to detect mycoplasma contamination sooner. However, realising their full potential requires robust validation, risk-based implementation and integration with a wider contamination-control strategy.
ArticleCHO perfusion model lifts yield by letting cellular waste build up
A hybrid model built into commercial software and running a self-driving bioreactor has found that unmeasured cellular waste, not the usual metabolites, throttles perfusion yields.
ReportPharma Horizons: Nitrosamines
EPR’s 2026 nitrosamines report covers the key developments in manufacturing, quality, regulation, analytical development and beyond.
ArticleMovement, speed and numbers: contribution of cleanroom operators to particle control
Tim Sandle explores the main factors that influence particle accumulation in pharmaceutical cleanrooms, advising how best to control risks and minimise operator contamination.
ReportPharma Horizons: Process Analytical Technology (PAT)
The definitive guide to transitioning from manual, offline batch testing to automated, continuous biomanufacturing.
ArticleTroubleshooting capping defects in brittle tablet formulations
Cam-driven technology optimises the compaction process by maintaining consistent tablet hardness across turret speeds, enabling robust, scalable manufacturing of capping-prone blends.
ArticleWhat Annex 22 spells for AI in GMP manufacturing
Europe’s first dedicated framework for artificial intelligence in GMP manufacturing is close to finalisation and it is more demanding and more consequential than many manufacturers may currently appreciate.
ArticleOptimising efficiency and yield through bioprocessing automation
A technical deep dive from Thermo Fisher Scientific reveals how closed-loop Raman spectroscopy is delivering measurable gains in mAb titer, product quality and downstream efficiency—while enabling fully autonomous perfusion processes running continuously for 19 days.